Technical analysis of Immuneering Corporation (IMRX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations.
Price Performance
| 1 month | -11.53% |
| 3 months | +0.91% |
| Year-to-date | -32.37% |
| 1 year | -44.86% |
| 3 years | -43.88% |
| 5 years | -84.38% |
52-Week Range
| 52-week High | $10.08 |
| 52-week Low | $3.86 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $4.77 |
| SMA 200 | $5.16 |
| Beta | 0.43 |
| 30-day Volatility (annualised) | 48.4% |
| Price vs SMA 50 | -6.7% |
| Price vs SMA 200 | -13.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.87 | |
| 2025-11 | $7.66 | +11.5% |
| 2025-12 | $6.58 | -14.1% |
| 2026-01 | $4.63 | -29.6% |
| 2026-02 | $4.99 | +7.8% |
| 2026-03 | $5.27 | +5.6% |
| 2026-04 | $5.24 | -0.6% |
| 2026-05 | $5.77 | +10.1% |
| 2026-06 | $4.99 | -13.5% |
| 2026-07 | $4.13 | -17.2% |
| 2026-08 | $4.99 | +20.8% |
| 2026-09 | $4.45 | -10.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 | | |
Price
| Price | $4.45 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.50 |
| EV / EBITDA | -2.24 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 19.47 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 11.19 |